CASI Pharmaceuticals Inc.: Launched EVOMELA® (melphalan for injection, multiple myeloma) in August 2019, only melphalan commercially available in China; advancing development of anti-CD19 T-cell therapy (CNCT19) in B-NHL and B-ALL and anti-CD38 mAb (CID-103) in multiple myeloma, focused on becoming China’s major hematology oncology company; reported $3.1 million revenue (3 months ending 3/31/20) for EVOMELA. Strategic BD approach enables opportunistic pipeline expansion.
Based in...
Asia, US - South Atlantic
Disease Space
Public, USA
Market Cap
100MM - 500MM
9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of CASI Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
IDG-Accel China Growth Fund III Associates LP 8.28 7,973,536 12.92 13F 6/30/20
The Vanguard Group, Inc. 2.88 2,780,125 4.50 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 2.52 2,430,228 3.94 13F 6/30/20
BlackRock Fund Advisors 1.86 1,789,291 2.90 13F 6/30/20
Wellington Shields & Co. LLC 1.65 1,585,609 2.57 13F 6/30/20
Wellington Shields Capital Management LLC 1.37 1,321,745 2.14 13F 6/30/20
BlackRock Institutional Trust Co. NA 1.36 1,313,858 2.13 13F 6/30/20
Ikarian Capital LLC 1.08 1,039,910 1.68 13F 6/30/20
State Street Corp. 0.99 955,232 1.55 13F 6/30/20
Geode Capital Management LLC 0.81 781,473 1.27 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.